Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLDX POWR Grades
- CLDX scores best on the Quality dimension, with a Quality rank ahead of 33.83% of US stocks.
- The strongest trend for CLDX is in Stability, which has been heading down over the past 179 days.
- CLDX ranks lowest in Stability; there it ranks in the 5th percentile.
CLDX Stock Summary
- CLDX's price/sales ratio is 1,660.3; that's higher than the P/S ratio of 99.75% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for CELLDEX THERAPEUTICS INC; that's greater than it is for only 7.11% of US stocks.
- As for revenue growth, note that CLDX's revenue has grown -90.44% over the past 12 months; that beats the revenue growth of just 1.29% of US companies in our set.
- Stocks that are quantitatively similar to CLDX, based on their financial statements, market capitalization, and price volatility, are NKTR, APLS, QRVO, LXRX, and FULC.
- Visit CLDX's SEC page to see the company's official filings. To visit the company's web site, go to www.celldex.com.
CLDX Valuation Summary
- CLDX's price/sales ratio is 1588.2; this is 34054.84% higher than that of the median Healthcare stock.
- Over the past 243 months, CLDX's price/earnings ratio has gone down 10.2.
Below are key valuation metrics over time for CLDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLDX | 2022-09-23 | 1588.2 | 3.6 | -13.1 | -12.9 |
| CLDX | 2022-09-22 | 1633.6 | 3.7 | -13.5 | -13.2 |
| CLDX | 2022-09-21 | 1647.2 | 3.7 | -13.6 | -13.3 |
| CLDX | 2022-09-20 | 1706.3 | 3.9 | -14.1 | -13.8 |
| CLDX | 2022-09-19 | 1673.9 | 3.8 | -13.8 | -13.6 |
| CLDX | 2022-09-16 | 1660.3 | 3.7 | -13.7 | -13.5 |
CLDX Growth Metrics
- Its 3 year price growth rate is now at 690.1%.
- Its 2 year price growth rate is now at 1169.46%.
- Its 4 year net income to common stockholders growth rate is now at 64.11%.
The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 0.824 | -77.673 | -99.654 |
| 2022-03-31 | 4.141 | -67.359 | -77.023 |
| 2021-12-31 | 4.651 | -60.909 | -70.511 |
| 2021-09-30 | 8.103 | -51.597 | -72.263 |
| 2021-06-30 | 8.618 | -47.086 | -66.035 |
| 2021-03-31 | 5.374 | -46.378 | -63.693 |
CLDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
- CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
- CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.
The table below shows CLDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.038 | 1 | -0.480 |
| 2021-03-31 | 0.022 | 1 | -0.447 |
| 2020-12-31 | 0.034 | 1 | -0.479 |
| 2020-09-30 | 0.024 | 1 | -0.470 |
| 2020-06-30 | 0.028 | 1 | -0.636 |
| 2020-03-31 | 0.038 | 1 | -0.864 |
CLDX Price Target
For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $64.83 | Average Broker Recommendation | 1.25 (Strong Buy) |
CLDX Stock Price Chart Interactive Chart >
CLDX Price/Volume Stats
| Current price | $27.98 | 52-week high | $57.20 |
| Prev. close | $28.78 | 52-week low | $19.85 |
| Day low | $27.11 | Volume | 554,100 |
| Day high | $28.59 | Avg. volume | 650,995 |
| 50-day MA | $31.84 | Dividend yield | N/A |
| 200-day MA | $31.33 | Market Cap | 1.31B |
Celldex Therapeutics Inc. (CLDX) Company Bio
Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.
Latest CLDX News From Around the Web
Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (CLDX – Research Report), Prothena (PRTA – Research Report) and Finch Therapeutics Group (FNCH – Research Report) with bullish sentiments. Celldex (CLDX) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Celldex today and set a price target of $73.00. The company's shares closed last Monday at $37.47. According to TipRanks. |
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue EstimatesCelldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane |
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaHAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. |
Billionaire Andreas Halvorsen Bets Big on These 2 High-Upside StocksEven after some recent positive trading sessions, the stock markets are still registering heavy losses this year. The S&P is down 18%, and the NASDAQ remains in bear territory with a 26% year-to-date loss. But these broad-based market losses have also opened up opportunities, as many stocks have fallen for no fault of their own. Some of the Street’s most legendary investors are not shying away from buying in, even in this bearish environment. Andreas Halvorsen, a former Tiger Cub and the billion |
CLDX Price Returns
| 1-mo | -11.15% |
| 3-mo | -3.98% |
| 6-mo | -21.51% |
| 1-year | -49.32% |
| 3-year | 1,195.37% |
| 5-year | -31.42% |
| YTD | -27.59% |
| 2021 | 120.55% |
| 2020 | 685.65% |
| 2019 | -25.67% |
| 2018 | -92.96% |
| 2017 | -19.77% |
Continue Researching CLDX
Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...